The genetic nature of constitutive activation of the RAS/RAF/MEK/ERK pathway in colorectal tumors with no B-raf or K-ras mutation remains unknown, although it may in part due to increased activity of growth factor receptor induced cell proliferation pathways. This evidence concerns the gene KRAS and colorectal neoplasm.